Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University’s CEBM and editor of BMJ Evidence)*
(1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice.
(4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients.
(11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc.
(17.46) Helen drops and EBM bombshell - is all the work needed to blind participants in a double blind randomised control trial actually worth it?
(33.00) Helen is annoyed about a press release from the department of health, and kicks of 2020 by stealing Carl's rant spot.
Corticosteroids for Treating Sepsis in Children and Adults
Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline
Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.
Fool’s gold? Why blinded trials are not always best
Impact of blinding on estimated treatment effects in randomised clinical trials
*quick note to say sorry about the sound quality on Duncan's microphone - we had a technical glitch (he was left alone to record).